Satellos Bioscience Inc.
Satellos Bioscience Inc. (MSLE): 1 pipeline candidate · ~2 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.1 months
D/E 0.15 · 0% dilution
Lead: Early Phase 1
1 candidate
N/A
N/A
A transparent, data-derived signal for Satellos Bioscience Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$121.9M
Cash
$9.8M
Quarterly Burn
$23.6M
Runway
2.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| sat-3247 | Early Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
26
Total value held
$27.1M
| Holder | Shares | Value |
|---|---|---|
| franklin resources inc | 938,666 | $5.3M |
| avidity partners management lp | 775,538 | $5.3M |
| sphera funds management ltd. | 489,207 | $2.8M |
| suvretta capital management, llc | 475,000 | $2.7M |
| adage capital partners gp, l.l.c. | 380,354 | $2.1M |
| saturn v capital management lp | 350,000 | $2.0M |
| millennium management llc | 298,433 | $1.7M |
| 683 capital management, llc | 230,833 | $1.3M |
| empery asset management, lp | 230,100 | $1.3M |
| adar1 capital management, llc | 222,555 | $1.3M |
Showing top 10 of 26 institutional holders of Satellos Bioscience Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Satellos Bioscience Inc.'s pipeline?
Satellos Bioscience Inc. (MSLE) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Satellos Bioscience Inc.'s lead drug candidate?
Satellos Bioscience Inc.'s most advanced tracked candidate is sat-3247 (Early Phase 1) for Duchenne Muscular Dystrophy; Duchenne Muscular Dystrophy (DMD).
What is Satellos Bioscience Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Satellos Bioscience Inc. has approximately 2.1 months of cash runway.
What is Satellos Bioscience Inc.'s market capitalization?
Satellos Bioscience Inc.'s market capitalization is approximately $121.9M.
Who is the CEO of Satellos Bioscience Inc.?
Mr. Francis Gleeson B.B.A. M.B.A is the chief executive officer of Satellos Bioscience Inc. (MSLE).
Get the full picture on Satellos Bioscience Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.